CN105982882B - A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid - Google Patents
A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid Download PDFInfo
- Publication number
- CN105982882B CN105982882B CN201510058942.XA CN201510058942A CN105982882B CN 105982882 B CN105982882 B CN 105982882B CN 201510058942 A CN201510058942 A CN 201510058942A CN 105982882 B CN105982882 B CN 105982882B
- Authority
- CN
- China
- Prior art keywords
- composition
- preparation
- recipe quantity
- tincture
- hemorrhoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 238000002360 preparation method Methods 0.000 title claims abstract description 86
- 208000014617 hemorrhoid Diseases 0.000 title claims abstract description 60
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 229940079593 drug Drugs 0.000 title claims abstract description 35
- 230000003287 optical effect Effects 0.000 title claims abstract description 23
- 239000007858 starting material Substances 0.000 title claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 title abstract description 20
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 claims abstract description 43
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- 238000003756 stirring Methods 0.000 claims description 53
- 229940098465 tincture Drugs 0.000 claims description 44
- 235000019441 ethanol Nutrition 0.000 claims description 42
- 239000002674 ointment Substances 0.000 claims description 41
- 239000004495 emulsifiable concentrate Substances 0.000 claims description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 18
- 239000011521 glass Substances 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 238000004090 dissolution Methods 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 239000011259 mixed solution Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 229930003448 Vitamin K Natural products 0.000 claims description 10
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 10
- 235000019168 vitamin K Nutrition 0.000 claims description 10
- 239000011712 vitamin K Substances 0.000 claims description 10
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 10
- 229940046010 vitamin k Drugs 0.000 claims description 10
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 9
- 230000032683 aging Effects 0.000 claims description 9
- 230000001804 emulsifying effect Effects 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000007906 compression Methods 0.000 claims description 7
- 230000006835 compression Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 229940099259 vaseline Drugs 0.000 claims description 5
- 239000004166 Lanolin Substances 0.000 claims description 4
- 229940039717 lanolin Drugs 0.000 claims description 4
- 235000019388 lanolin Nutrition 0.000 claims description 4
- -1 creme Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims 4
- 230000000694 effects Effects 0.000 abstract description 49
- 231100000331 toxic Toxicity 0.000 abstract description 8
- 230000002588 toxic effect Effects 0.000 abstract description 8
- 230000035876 healing Effects 0.000 abstract description 7
- 230000036407 pain Effects 0.000 abstract description 6
- 230000008961 swelling Effects 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 238000005469 granulation Methods 0.000 abstract description 2
- 230000003179 granulation Effects 0.000 abstract description 2
- 230000023597 hemostasis Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 46
- 210000003491 skin Anatomy 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 23
- 210000000436 anus Anatomy 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000003542 behavioural effect Effects 0.000 description 11
- 229920000742 Cotton Polymers 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000002075 main ingredient Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 229960004063 propylene glycol Drugs 0.000 description 9
- 230000002195 synergetic effect Effects 0.000 description 7
- 206010059866 Drug resistance Diseases 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 241000972155 Moschus Species 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241000675108 Citrus tangerina Species 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000402754 Erythranthe moschata Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000015815 Rectal disease Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- YZSJUQIFYHUSKU-UHFFFAOYSA-N ethanol;propane-1,2-diol Chemical compound CCO.CC(O)CO YZSJUQIFYHUSKU-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000019751 Anorectal disease Diseases 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- 206010057765 Procedural complication Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000005167 amoeboid movement Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000018127 platelet degranulation Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
It the invention discloses a kind of optical active starting materials composition, is made with following raw materials according：Left-handed muskone, dencichine.Hemorrhoid can be effectively treated the present invention provides a kind of, therapeutic effect is good, it is quick, do not recur, have no toxic side effect, to control difficulty in relapse after healing, bioavailability high, drug is conducive to the optical active starting materials composition that human skin absorbs, and the external preparation as made from the composition, it is short to the treatment cycle of hemorrhoid, therapeutic effect is good, quick, control difficulty in relapse after healing, and have no toxic side effect, there is apparent anti-inflammatory, pain easing and hemostasis function, there is the apparent hemorrhoid effect that disappears for eliminating granulation swelling.Composition and its external preparation provided by the invention, can effectively treat internal piles, external piles and mixed hemorrhoid, the treatment to hemorrhoid, cure rate and efficient higher, and cure rate is up to 93.9%, effective percentage 100%.
Description
Technical field
The invention belongs to field of medicaments, in particular to a kind of externally applied drug of optical active starting materials composition prescription therapeutic hemorrhoid
And preparation process.
Technical background
Anal and bowel pile is the distinctive common disease of the mankind, frequently-occurring disease.Data shows that the disease incidence of anorectal disease is
59.1%, it is 87.25% that hemorrhoid, which account for the ratio in all anorectal diseases, and wherein most commonly seen with internal piles, accounts for all anal intestine diseases
The 52.19% of disease；Men and women can fall ill, and the disease incidence of women is 67%, and the disease incidence of male is 53.9%；Any age all may be used
Morbidity, wherein 20-40 people from year old is more common, modern medicine to the treatment of hemorrhoid include used in Chinese medicine, external application and doctor trained in Western medicine operation
The methods of.The treatment of hemorrhoid at present is eliminated the excessive varicose of vein and is filled mainly to improve crissum and haemorrhoidal vein blood circulation,
Treatment aspect is based on performing the operation, but Intra operative complica-tions are relatively more, is in addition easy a lot of patients of recurrence and is reluctant to perform an operation
Reason, effect are not ideal；In the drug of existing treatment hemorrhoid, have using Moschus as made from raw material, and currently on the market
Medicinal Moschus is divided into two kinds i.e. natural musk and muscone, left-handed muskone be bioactive ingredients in natural musk and
Aromatic core, content are only 1.5% to 2.0%, though raceme muskone is effective to hemorrhoid, effect is not obvious.China
102885893 A of patent CN discloses a kind of pharmaceutical composition for treating hemorrhoid, and the Chinese medicine composition is with Moschus, borneol, copper
Green, Semen Strychni, alum traditional Chinese medicine of the five flavours are made for raw material, and wherein the usage amount of Moschus defines left-handed muskone effective dose,
Although the product can treat hemorrhoid, its bioavilability is not high, slow to responding well to treatment for hemorrhoid, easy to recur；And raw material is more,
Whether its compatibility properly also needs to be investigated, and preparation method is complicated.
Summary of the invention
The object of the present invention is to provide one kind using left-handed muskone with optical activation as made from primary raw material, can have
Effect treatment hemorrhoid, therapeutic effect is good, it is quick, have no toxic side effect, control difficulty in relapse after healing, drug and absorbed conducive to human skin,
The high optical active starting materials composition of bioavilability；
Additionally, it is provided treating the preparation of hemorrhoid and the preparation method of preparation as made from this composition；
In addition, also providing the purposes of this composition.
Optical active starting materials composition of the invention, is prepared by the bulk pharmaceutical chemicals of following parts by weight：
Left-handed muskone 30-200 dencichine 10-100.
Optical active starting materials composition provided by the present invention, raw material is few, easy processing, and the composition has hemorrhoid fine
Therapeutic effect, no dependence has no toxic side effect；Internal piles, external piles, mixed hemorrhoid can effectively be treated.
Left-handed muskone and raceme muskone are two different drugs, optics drugs prescription and no optical activity
Medicament composing prescription has substantive change；Using left-handed muskone with optical activation as primary raw material, composition obtained, drug
Purity significantly improves, and dosage halves；Drug effect improves；The toxic side effect of another enantiomer is eliminated, the major ingredient in prescription is single
One active enantiomers, chemical property is clear, can meet the quality analysis and control condition of reproducibility；It is suitble to Chinese medicine and international standard
The progress direction to integrate with is also beneficial to the wild resource protection of raw material；Meanwhile the collaboration of dencichine and left-handed muskone is made
With, so that drug obtained significantly improves the therapeutic effect of hemorrhoid, significant effect.
Preferably, composition of the invention is prepared by the bulk pharmaceutical chemicals of following parts by weight are processed：
Left-handed 115 dencichine 55 of muskone.
The optical active starting materials composition can effectively treat hemorrhoid, and quick, no dependence has no toxic side effect, effect
Significantly.
Composition of the invention, main ingredient only use two taste bulk pharmaceutical chemicals of left-handed muskone and dencichine, do not need that it is added
Its bulk pharmaceutical chemicals, so that it may good therapeutic effect is played to hemorrhoid, treatment cycle is short, and it is rapid-action, it does not recur, has no toxic side effect,
No dependence.
Preparation made from composition and auxiliary material of the invention, preparation include tincture, abrasive cleaner, ointment, emulsifiable concentrate, frost
Agent, suppository, film, transdermal patch, paste or liniment.
Further, preparation is tincture, and tincture includes the composition and auxiliary material of following parts by weight composition：
60-80% ethyl alcohol refers to the ethyl alcohol of 60-80% (ml/ml).
Concentration of alcohol, using expression way as defined in the pharmacopeia note on the use, i.e., " % (ml/ml) ".
Most external drugs must be reached in target cell and be played a role, and lesion cell may due to drug can not or compared with
Slow enters cell and expected therapeutic effect is not achieved, left-handed muskone and dencichine, though there is specific bioactivity,
It is that Special Significance is had no by the osmosis of two main thoroughfare phases of skin resistance for drug, it is considered that, influence drug
Permeating main two channels by skin resistance is mutually：Intracellular hydrophilic protein egg polarity channel, the non-pole of iuntercellular lipoids
Property channel phase, it is related with the solubility of drug and pharmaceutical carrier to solve the principal element of diffusional resistance.
80% ethyl alcohol and the unlimited ratio of left-handed muskone are solvable, and the hydrophily of 1.2 propylene glycol makes it to penetrate into polarity channel
Savings is formed, dissolving cuticula a- albumen and forming hydrogen bond promotion skin hydration therewith reduces channel resistance.Ethyl alcohol is amphipathic
Solvent, can swellable hydrophilic albumen can also extract lipoids, ethyl alcohol and 1,2 propylene glycol, which are used in combination, can increase drug in each phase
And the distribution coefficient and diffusion coefficient of film two sides, increase infiltration rate, left-handed muskone is that native configurations macrocyclic ketone has class
Like the chemical structure efficiency relationship of Stratum corneum lipids, double bond structure, which forms asymmetric space effectively, influences the rouge in space between cells
Matter structure enhances the mobility of lipoids thus can also promote the transdermal operating of lipophilic drugs, and the two compound system is to main ingredient
Dissolution and delivery can effectively pass through the hydrophilic and oleophilic channel of skin multilayer.
The lytic agent and carrier systems of the left-handed muskone of main ingredient and dencichine in the present invention are ethyl alcohol, 1.2- propylene glycol
Compound system.Thus the compound system has significant anatonosis effect to the targeting delivery of left-handed muskone.
In turn, also effect with synergy, selection have targeting to the lytic agent of drug carrier systems formed therewith
The single-activity enantiomer of meaning can reduce the other racemic drugs of joint as main ingredient；And the Chinese medicine raw medicine of complicated component
Dosage reduces the adverse reaction of toxicity and host, enhances to the synergistic effect of target cell selectivity and to host selectable
The anti-effect of tangerine, direct covalent bonds combination between the two may will form molecule with more bioactivity, for subcutaneous cell
Different macromolecular receptors generates one or two kinds of mutation, thus so that receptor is coped with two kinds of single-activity enantiomers while produce
A possibility that raw drug resistance, is smaller.
Tincture is external preparation, overcome suppository need rectal, to it is artificial at psychological burden, be unfavorable for patient restore
The shortcomings that, it is directly absorbed by anus portion skin, effect is good, without side-effects；While guaranteeing effectively to treat patient, also
Human body can be promoted to fully absorb effective component in tincture, therapeutic efficiency is improved, shorten treatment time, -1.2 propylene glycol of ethyl alcohol
System enhances the transdermal coefficient of external-use tincture delivery main ingredient, guarantees the healing curative effect of tincture.
Further, preparation is ointment, and ointment includes the composition and auxiliary material of following parts by weight composition：
Ointment is external preparation, is directly absorbed by anus portion skin, and effect is good, without side-effects, meanwhile, ointment is in skin
The time retained on skin is longer, is more advantageous to the sustained release to anus portion skin；It is same guaranteeing effectively to treat patient
When, moreover it is possible to promote human body to fully absorb effective component in ointment, improves therapeutic efficiency, shortens treatment time.
Further, preparation is ointment, and ointment includes the composition and auxiliary material of following parts by weight composition：
Further, preparation is emulsifiable concentrate, and emulsifiable concentrate includes the composition and auxiliary material of following parts by weight composition：
Emulsifiable concentrate is external preparation, is directly absorbed by anus portion skin, effect is good, without side-effects；Meanwhile emulsifiable concentrate is in skin
The time retained on skin is longer, is more advantageous to the sustained release to anus portion skin, also can guarantee moisturizing and shield to anus portion skin
Reason；While guaranteeing effectively to treat patient, moreover it is possible to promote human body to fully absorb effective component in emulsifiable concentrate, mention
High therapeutic efficiency shortens treatment time.
Further, preparation is emulsifiable concentrate, and emulsifiable concentrate includes the composition and auxiliary material of following parts by weight composition：
The synergistic effect of auxiliary material is conducive to the dissolution rate for improving active constituent in emulsifiable concentrate, further increases living in preparation
Property ingredient bioavilability, promote absorption of the human body to effective component, increase the using effect of drug, hemorrhoid are controlled in shortening
Treat period, effect it is good, it is quick, control difficulty in relapse after healing.
The preparation method of ointment of the invention, includes the following steps：
(1) dencichine of recipe quantity is ground into fine powder 1, by the left-handed muskone and ethyl alcohol of recipe quantity with 1:2 weight
Amount portion rate mixes to obtain solution 1, and the fine powder 1 and solution 1 are uniformly mixed, and composition is made；
(2) vitamin K for entering recipe quantity in the composition obtained to step (1) continuously adds recipe quantity after completely dissolution
Dimethyl sulfoxide and 1,2-PD, sufficiently dissolution and after mixing, obtain A mixture；
(3) atoleine of recipe quantity, vaseline, glycerin monostearate, glycerol, octadecanol and purified water are placed in
It is heated to 75-80 DEG C in glass reaction kettle, when at the uniform velocity stirring 20-25min is down to 35-45 DEG C to kettle temperature, step (2) is added and obtain
A mixture, continue stir 15-20min, stop heating and stirring；Then raw material in kettle is placed in vacuum homogeneous emulsifying machine
Emulsification, is cooled to room temperature to get ointment.
The preparation method of emulsifiable concentrate of the invention, includes the following steps：
(1) dencichine of recipe quantity is ground into fine powder 1, by the left-handed muskone and ethyl alcohol of recipe quantity with 1:2 weight
Amount portion rate mixes to obtain solution 1, and the fine powder 1 and solution 1 are uniformly mixed, and composition is made；
(2) vitamin K of recipe quantity is added in the composition obtained to step (1), sufficiently dissolves, obtains mixed solution II,
It is spare；
(3) lanolin of recipe quantity, glycerin monostearate, octadecanol and purified water are placed in glass reaction kettle and are added
Heat is to 75-80 DEG C, and when at the uniform velocity stirring 5-10min is down to 35-45 DEG C to kettle temperature, the mixed solution II that step (2) obtain is added, after
Continuous stirring 5-15min, stops heating and stirring；Then raw material in kettle is placed in vacuum homogeneous emulsifying machine and is emulsified, be cooled to room
Temperature is to get emulsifiable concentrate.
Beneficial effects of the present invention are：
(1), prescription raw material is simple, type is few, and left-handed muskone is that the androsterone hormone like substance of native configurations is also thin
Born of the same parents' cytochrome p 450 enzyme system inducer has resuscitation with aromatics, clearing and activating the channels and collaterals, swelling and pain relieving and anti-inflammatory effect, and dencichine is also a kind of
Native configurations l-amino acid substance has dissipating stasis and stanching bleeding, the effect of detumescence ding-tong.Its chemical structure names is：β-N-oxalo-
L- α, β-diaminopro 2pionic acid. can make blood platelet viscosity do amoeboid movement, and keep cell membrane disruption and part molten
Solution generates the reaction of blood platelet degranulation, so that intra platelet free calcium ADP is induced, the styptic activities object such as antihemophilic factor II and Ca2+
Matter plays pharmacological action.
Two kinds of raw materials all have the optical activity property of native configurations, and are all single-activity enantiomer, single to make medication
Object targeting mechanism is clear, and the indication of two medicine drug combinations is：
Play clearing and activating the channels and collaterals, swelling and pain relieving, the synergistic effect of antibacterial anti-inflammatory and dissipating stasis and stanching bleeding, to heighten the effect of a treatment, delay or
Reduce the appearance of drug-fast bacteria；The combined use of two medicines can expand anti-inflammatory range；Individual doses are reduced, antagonism or toxicity are reduced.
It is generally acknowledged that:Single-activity enantiomer similar in two kinds of pharmacology is used in combination and antagonism person occurs and only accounts for 3%
~5%, the chance that synergistic effect is obtained after flora breeding period is used in combination with resting stage targeting two medicine of environment increases；Relatively
Issuable mechanism of drug resistance when being better than individually using left-handed muskone or dencichine as raw material；Such as：Inactivator, change target,
Change logical, forced-ventilated etc. and increase antagonism, thus has the function of synergy.
(2) preparation process provided by the present invention, it is simple to operation；The two kinds of optics realized again in composition simultaneously are living
Property single enantiomer combination without side-effects；External preparation obtained, both improves drug safety, is also easy to human skin suction
Receive, the main ingredient drug targeting mechanism of action is clear in preparation, shorten the treatment cycle to hemorrhoid, it is quick, control difficulty in relapse after healing.
(3) external preparation for the treatment of hemorrhoid of the invention, it is with optics that primary raw material, which is levo form muskone, in prescription
Active native configurations raw material, in prescription major ingredient and auxiliary material physicochemical property can chemistry quantify, curative effect specificity is obvious.
Specific embodiment
Below with reference to embodiment, the invention will be further described：
Example 1 group closes object
Prescription：
Left-handed muskone 30g dencichine 10g
Preparation method：
The dencichine of recipe quantity is ground into fine powder 1, by the left-handed muskone and ethyl alcohol of recipe quantity with 1:2 parts by weight
Number ratio mixes to obtain solution 1, and the fine powder 1 and solution 1 are uniformly mixed, and composition is made.
2 composition of embodiment
A kind of optical active starting materials composition, the composition processed are prepared by the bulk pharmaceutical chemicals of following parts by weight：
Left-handed muskone 200g dencichine 100g
Preparation method：Composition is made according to the preparation method of embodiment 1.
3 composition of embodiment
Prescription：
Left-handed muskone 115g dencichine 55g
Preparation method：Composition is made according to the preparation method of embodiment 1.
4 tincture of embodiment
Prescription：
Preparation method：
(1) according to the preparation method of embodiment 1, composition is made；
(2) composition that step (1) obtains is placed in glass reaction kettle and is heated to 30 DEG C, at the uniform velocity stirring 15min, stirring
While sequentially add the 1,2-PD of the dimethyl sulfoxide of recipe quantity, the ethyl alcohol of recipe quantity, recipe quantity, keep 30 DEG C of temperature
Degree, and continue to stir 20min to being uniformly mixed, stop heating, it, will be empty from the compression that pressure is 0.08Mpa after being cooled to room temperature
Material bottom is introduced at the reacted kettle feed opening of Φ 10mm hose accessed on gas cylinder, brushes 60min, after being then allowed to stand 3h ageing
Light yellow transparent liquid is obtained to get tincture.
5 tincture of embodiment
Prescription：
Preparation method：
(1) according to the preparation method of embodiment 2, composition is made；
(2) composition that step (1) obtains is placed in glass reaction kettle and is heated to 35 DEG C, at the uniform velocity stirring 20min, stirring
While sequentially add the 1,2-PD of the dimethyl sulfoxide of recipe quantity, the ethyl alcohol of recipe quantity, recipe quantity, keep 35 DEG C of temperature
Degree, and continue to stir 30min to being uniformly mixed, stop heating, it, will be empty from the compression that pressure is 0.08Mpa after being cooled to room temperature
Material bottom is introduced at the reacted kettle feed opening of Φ 10mm hose accessed on gas cylinder, brushes 60min, after being then allowed to stand 5h ageing
Light yellow transparent liquid is obtained to get tincture.
6 tincture of embodiment
Prescription：
Preparation method：
(1) according to the preparation method of embodiment 3, composition is made；
(2) composition that step (1) obtains is placed in glass reaction kettle and is heated to 33 DEG C, at the uniform velocity stirring 18min, stirring
While sequentially add the 1,2-PD of the dimethyl sulfoxide of recipe quantity, the ethyl alcohol of recipe quantity, recipe quantity, keep 33 DEG C of temperature
Degree, and continue to stir 25min to being uniformly mixed, stop heating, it, will be empty from the compression that pressure is 0.08Mpa after being cooled to room temperature
Material bottom is introduced at the reacted kettle feed opening of Φ 10mm hose accessed on gas cylinder, brushes 60min, after being then allowed to stand 4h ageing
Light yellow transparent liquid is obtained to get tincture.
7 ointment of embodiment
Prescription：
Preparation method：
(1) according to the preparation method of embodiment 1, composition is made；
(2) vitamin K for entering recipe quantity in the composition obtained to step (1) continuously adds recipe quantity after completely dissolution
Dimethyl sulfoxide and 1,2-PD, sufficiently dissolution and after mixing, obtain A mixture；
(3) atoleine of recipe quantity, vaseline, glycerin monostearate, glycerol, octadecanol and purified water are placed in
It is heated to 80 DEG C in glass reaction kettle, when at the uniform velocity stirring 25min is down to 35 DEG C to kettle temperature, the A mixing that step (2) obtain is added
Object continues to stir 15min, stops heating and stirring；Then raw material in kettle is placed in vacuum homogeneous emulsifying machine and is emulsified, is cooled to
Room temperature is to get ointment.
8 ointment of embodiment
Prescription：
Preparation method：Ointment is made according to the preparation method of embodiment 7.
9 ointment of embodiment
Prescription：
Preparation method：Ointment is made according to the preparation method of embodiment 7.
10 emulsifiable concentrate of embodiment
Prescription：
Preparation method：
(1) according to the preparation method of embodiment 1, composition is made；
(2) vitamin K of recipe quantity is added in the composition obtained to step (1), sufficiently dissolves, obtains mixed solution I, it is standby
With；
(3) lanolin of recipe quantity, glycerin monostearate, octadecanol and purified water are placed in glass reaction kettle and are added
Heat is to 75 DEG C, when at the uniform velocity stirring 10min is down to 45 DEG C to kettle temperature, the mixed solution I that step (2) obtain is added, continues to stir
15min stops heating and stirring；Then raw material in kettle is placed in vacuum homogeneous emulsifying machine and is emulsified, is cooled to room temperature to get cream
Finish.
11 emulsifiable concentrate of embodiment
Prescription：
Preparation method：Emulsifiable concentrate is made according to the preparation method of embodiment 10.
12 emulsifiable concentrate of embodiment
Prescription：
Preparation method：Emulsifiable concentrate is made according to the preparation method of embodiment 10.1 tincture of comparative examples
Prescription：
Preparation method：
(1) by the left-handed muskone and ethyl alcohol of recipe quantity with 1:2 weight fraction ratio mixes, and obtains composition；
(2) composition that step (1) obtains is placed in glass reaction kettle and is heated to 33 DEG C, at the uniform velocity stirring 18min, stirring
While sequentially add the 1,2-PD of the dimethyl sulfoxide of recipe quantity, the ethyl alcohol of recipe quantity, recipe quantity, keep 33 DEG C of temperature
Degree, and continue to stir 25min to being uniformly mixed, stop heating, it, will be empty from the compression that pressure is 0.08Mpa after being cooled to room temperature
Material bottom is introduced at the reacted kettle feed opening of Φ 10mm hose accessed on gas cylinder, brushes 60min, after being then allowed to stand 4h ageing
Light yellow transparent liquid is obtained to get tincture.
2 ointment of comparative examples
Prescription：
Preparation method：
(1) by the left-handed muskone and ethyl alcohol of recipe quantity with 1:2 weight fraction ratio mixes, and obtains composition；
(2) vitamin K that recipe quantity is added in the composition obtained to step (1) continuously adds prescription after completely dissolution
The dimethyl sulfoxide and 1,2-PD of amount, sufficiently dissolution and after mixing, obtain A mixture；
(3) atoleine of recipe quantity, vaseline, glycerin monostearate, glycerol, octadecanol and purified water are placed in
It is heated to 80 DEG C in glass reaction kettle, when at the uniform velocity stirring 25min is down to 35 DEG C to kettle temperature, the A mixing that step (2) obtain is added
Object continues to stir 15min, stops heating and stirring；Then raw material in kettle is placed in vacuum homogeneous emulsifying machine and is emulsified, is cooled to
Room temperature is to get ointment.
3 emulsifiable concentrate of comparative examples
Prescription：
Wherein, the concentration of the ethyl alcohol is 75%；
Preparation method：
(1) by the left-handed muskone and ethyl alcohol of recipe quantity with 1:2 weight fraction ratio mixes, and obtains composition；
(2) vitamin K of recipe quantity is added in the mixed solution I obtained to step (1), sufficiently dissolves, obtains mixed solution
I, it is spare；
(3) lanolin of recipe quantity, glycerin monostearate, octadecanol and purified water are placed in glass reaction kettle and are added
Heat is to 75 DEG C, when at the uniform velocity stirring 10min is down to 45 DEG C to kettle temperature, the mixed solution I that step (2) obtain is added, continues to stir
15min stops heating and stirring；Then raw material in kettle is placed in vacuum homogeneous emulsifying machine and is emulsified, is cooled to room temperature to get cream
Finish.
4 tincture of comparative examples
Prescription：
Preparation method：
(1) according to the preparation method of embodiment 1, composition is made；
(2) vegetable oil of the vitamin K recipe quantity of recipe quantity is dissolved, obtains mixed solution I, it is spare；
(3) composition that step (1) obtains and the mixed solution I that step (2) obtains are sequentially placed into glass reaction kettle
33 DEG C are heated to, at the uniform velocity stirring 18min, stirring while sequentially adds the dimethyl sulfoxide of recipe quantity, the ethyl alcohol of recipe quantity, protects
33 DEG C of temperature is held, and continues to stir 25min to being uniformly mixed, stops heating, after being cooled to room temperature, will be from pressure
Material bottom is introduced at the reacted kettle feed opening of Φ 10mm hose accessed on the compressed air bottle of 0.08Mpa, brushes 60min,
Light yellow transparent liquid is obtained after being then allowed to stand 4h ageing to get tincture.
5 ointment of comparative examples
Prescription：
Preparation method：
(1) according to the preparation method of embodiment 1, composition is made；
(2) vitamin K that recipe quantity is added in the composition obtained to step (1) continuously adds prescription after completely dissolution
The dimethyl sulfoxide of amount, sufficiently dissolution and after mixing, obtain A mixture；
(3) atoleine of recipe quantity, vaseline, glycerin monostearate, glycerol, octadecanol and purified water are placed in
It is heated to 80 DEG C in glass reaction kettle, when at the uniform velocity stirring 25min is down to 35 DEG C to kettle temperature, the A mixing that step (2) obtain is added
Object continues to stir 15min, stops heating and stirring；Then raw material in kettle is placed in vacuum homogeneous emulsifying machine and is emulsified, is cooled to
Room temperature is to get ointment.
1 stability test of test example
1. accelerated test
The tincture of Example 6 is divided into 3 batches, and number is sample 1, sample 2 and sample 3 respectively, at 30 DEG C ± 2 DEG C of temperature
Under, relative humidity is placed 6 months under conditions of being 65% ± 5%, 1 month during test, 2 months, 3 months, 6 the end of month point
Qu Yang not be primary, by the regulation in Chinese Pharmacopoeia, the character of tincture is detected, as a result, it has been found that, indices have no significant change；
The ointment of Example 9 is tested under similarity condition, as a result identical；
The tincture of comparative examples 4 is taken, is tested under similarity condition, as a result, it has been found that, the character of tincture is substantially change；
The ointment of comparative examples 5 is taken, is tested under similarity condition, as a result, it has been found that, the character of ointment obviously changes
Become.
2. long term test
The tincture of Example 6 is divided into 3 batches, and number is sample 1, sample 2 and sample 3 respectively, at 25 DEG C ± 2 DEG C of temperature
Under, relative humidity be 60% ± 10% under conditions of place 24 months, 0 month during test, 3 months, 6 months, 9 months,
12 months, 18 months, 24 the end of month it is separately sampled primary, by the regulation in Chinese Pharmacopoeia, detect the character of tincture, as a result send out
Existing, indices have no significant change；
The ointment of Example 9 is tested under similarity condition, as a result identical；
The tincture of comparative examples 4 is taken, is tested under similarity condition, as a result, it has been found that, the character of tincture is substantially change；
The ointment of comparative examples 5 is taken, is tested under similarity condition, as a result, it has been found that, the character of ointment obviously changes
Become.
By stability test it is found that preparation of the invention, stability are high；What 1,2 propylene glycol and ethyl alcohol were set in the present invention
Stirring sufficiently miscible and air in temperature and brushing ageing can make the chemical molecular of auxiliary material with the thermal diffusion of temperature difference motive force,
To stir the diffusion of the pressure under external force, the homogeneity for promoting solution to be formed enhances the stability of preparation.
2 propylene glycol of test example-ethanol system pharmacodynamics test
1. subjects：
It is directed the SD big white mouse for stimulating and suffering from hemorrhoid, China Medicine University's animal center provides.
Test group 1：100, female mice 50, male mouse 50,5 week old of age；
Test group 2：100, female mice 50, male mouse 50,5 week old of age；
Control group 1：100, female mice 50, male mouse 50,5 week old of age；
Control group 2：100, female mice 50, male mouse 50,5 week old of age.
2. test method：
Test group 1：SD mouse is taken, the hair in anus portion is carefully wiped out, exposes anus portion skin, 20mg absorbent cotton is transformed into 1cm x
2cm size is laid at the anus portion skin of exposing, with the tincture wetting absorbent cotton of embodiment 6, covers preservative film, solid with adhesive plaster
It is fixed, maintain sealing state, in 0,2,5,8,12,18, the behavioral indicator that records test mice respectively for 24 hours, every physical signs, and
It takes a blood sample to test mice and measures blood concentration；After mouse hemorrhoid are good, it is allowed to suffer from hemorrhoid again with same targeted stimulation,
And it is ditto tested；Long run test 5 times；
Test group 2：SD mouse is taken, the hair in anus portion is carefully wiped out, exposes anus portion skin, 20mg absorbent cotton is transformed into 1cm x
2cm size is applied to absorbent cotton with the ointment of embodiment 9, absorbent cotton is contained to the anus for being covered in exposing on one side of ointment
At portion's skin, cover preservative film, with immobilization with adhesive tape, maintain sealing state, in 0,2,5,8,12,18, record test is small respectively for 24 hours
The behavioral indicator of mouse, every physical signs, and take a blood sample to test mice and measure blood concentration；After mouse hemorrhoid are good, with same
The targeted stimulation of sample allows it to suffer from hemorrhoid again, and is ditto tested it；Long run test 5 times；
Control group 1：SD mouse is taken, the hair in anus portion is carefully wiped out, exposes anus portion skin, 20mg absorbent cotton is transformed into 1cm x
2cm size, with the tinctures of comparative examples 4 wetting absorbent cotton, cover preservative film, with immobilization with adhesive tape, maintain sealing state, in 0,
2, the behavioral indicator that 5,8,12,18, records test mice respectively for 24 hours, every physical signs, and test mice is taken a blood sample and measured
Blood concentration；After mouse hemorrhoid are good, it is allowed to suffer from hemorrhoid again with same targeted stimulation, and ditto tested it；
Long run test 5 times；
Control group 2：SD mouse is taken, the hair in anus portion is carefully wiped out, exposes anus portion skin, 20mg absorbent cotton is transformed into 1cm x
2cm size, be applied to absorbent cotton with the ointment of comparative examples 5, absorbent cotton contains to ointment be covered in exposing on one side
Anus portion skin at, cover preservative film, with immobilization with adhesive tape, maintain sealing state, in 0,2,5,8,12,18, record examination respectively for 24 hours
Behavioral indicator, the items physical signs of mouse are tested, and takes a blood sample to test mice and measures blood concentration；After mouse hemorrhoid are good,
It allows it to suffer from hemorrhoid again with same targeted stimulation, and it is ditto tested；Long run test 5 times.
3. statistical method：Respectively test 0,2,5,8,12,18, for 24 hours and after the test observation period for 24 hours at the end of,
It records every behavioral indicator of two groups of mouse and every physical signs, blood sampling and measures its blood concentration, behavioral indicator includes recognizing
Know that index, indicator reaction, motion index, physical signs include general physical signs, hematological indices, organ coefficient, tissue/dirty
The histopathologic examination etc. of device.
4. test result：
(1) blood concentration
The first round test in, the mouse of test group 1 and test group 2 respectively different times blood concentration record and it is right
It is recorded respectively in the blood concentration of different times according to the mouse of group 1 and control group 2, in each stage of medication, 1 He of test group
The blood concentration of 2 mouse of test group is significantly greater than the blood concentration of 2 mouse of control group 1 and control group；
This shows in the external application preparation of optical active starting materials composition prescription therapeutic hemorrhoid of the invention, propylene glycol-second
The use of alcohol system has apparent anatonosis to act on main ingredient, and also there is the carrier of drug carrier systems formed therewith collaboration to make
Effect.
(2) behavioral indicator and physical signs
In first round test, the mouse of test group 1 and test group 2 is respectively in the every behavioral indicator and items of different times
Physical signs record, in each stage of medication, every behavioral indicator and every physical signs are showed no notable difference, just
In normal range, even if slightly difference, within the observation period of later period for 24 hours, also restore normal, this shows occur during administration
Abnormal, this exception is also reversible after drug withdrawal；Two groups of mouse are also showed no obviously in every physical signs of different phase
Difference；
In first round test, the mouse of control group 1 and control group 2 is respectively in the every behavioral indicator and items of different times
Physical signs record, in each stage of medication, there is notable difference, not in the normal range in every behavioral indicator, including
Slow in reacting, restless, also there is notable difference, not in the normal range, and the observation period in the later period for 24 hours in every physical signs
It is interior, it can not restore normal；
This shows in the external application preparation of optical active starting materials composition prescription therapeutic hemorrhoid of the invention, propylene glycol-second
The use of alcohol system can also reach following effects：Toxicity and the adverse reaction of host can be reduced, is enhanced to target cell selectivity
It acts synergistically and to the anti-effect of the tangerine of host selectable；Ethyl alcohol bactericidal effect is very fast, and Disinfection Effect is reliable, small to people's irritation,
Nontoxicity acts on bacterial cell and plays dehydration first, and ethanol molecule enters the peptide chain link of protein molecule, makes
Denaturation precipitating occurs for protein；This act under 75% content seems stronger.For destroying bacteria cell wall, it may have very
Strong osmosis, 60%~85% ethyl alcohol are easier to penetrate into thallus, so that bacterial cell destroys dissolution, ethyl alcohol is logical
Inhibition bacterium enzyme system is crossed, its eubolism and growth and breeding are hindered；The viscosity and good hygroscopicity of 1,2 propylene glycol combine system
The irritation of ethyl alcohol exclusive use can be reduced.
(3) long run test
In first round test and subsequent 5 wheel long run test, the mouse of test group 1 and test group 2 uses same agent
Amount treatment similarly can be cured in the time similar, this shows the mouse of test group 1 and test group 2 not to institute's medication
Object develops drug resistance；
And in first round test and subsequent 5 wheel long run test, the mouse of control group 1 and control group 2 is used similarly
Dosage treatment is cured the time used and is increasingly grown, this shows that the mouse of control group 1 and control group 2 produces drug used
Drug resistance；
This shows in the external application preparation of optical active starting materials composition prescription therapeutic hemorrhoid of the invention, left-handed Moschus
Ketone combines the use of 1.2 propylene glycol-ethanol system with dencichine, can reduce a possibility that drug resistance generates.
5. conclusion：In the external application preparation of optical active starting materials composition prescription therapeutic hemorrhoid of the invention, left-handed Moschus
Ketone combines the use of 1.2 propylene glycol-ethanol system with dencichine, has good anatonosis effect to main ingredient, ethyl alcohol is to main ingredient
Reactivity and 1, the viscosity and hygroscopicity of 2 propylene glycol can extend drug treating time, enhance main ingredient drug effect, reduce treatment
Time limit；Meanwhile adverse reaction of the side effects of pharmaceutical drugs to host can be reduced, the synergistic effect for combining system enhances target cell choosing
Selecting property also reduces the anti-effect of tangerine of host；And a possibility that drug resistance generation.
3 clinical test of test example
1. hemorrhoid
1. case selection：
Treatment group 1：It is 33, the age 14-50 years old, 30 years old, the course of disease 2-7 weeks average；
Treatment group 2：It is 33, the age 14-50 years old, 30 years old, the course of disease 2-7 weeks average；
Treatment group 3：It is 33, the age 14-50 years old, 30 years old, the course of disease 2-7 weeks average；
Control group 1：It is 33, the age 14-50 years old, 30 years old, the course of disease 2-7 weeks average；
Control group 2：It is 33, the age 14-50 years old, 30 years old, the course of disease 2-7 weeks average；
Control group 3：It is 33, the age 14-50 years old, 30 years old, the course of disease 2-7 weeks average；
Control group 4：It is 33, the age 14-50 years old, 30 years old, the course of disease 2-7 weeks average.
2. administration mode：
Treatment group 1：Using the tincture of the treatment hemorrhoid of embodiment 6, preceding use is slept, one time a day, patient cleans affected part, will
Tincture is embrocated in the affected part of patient, 15 days as a treatment course, and two courses for the treatment of are used continuously；
Treatment group 2：Using the ointment of the treatment hemorrhoid of embodiment 9, preceding use is slept, one time a day, patient cleans affected part,
Ointment is coated in the affected part of patient, two courses for the treatment of are used continuously in 15 days as a treatment course；
Treatment group 3：Using the emulsifiable concentrate of the treatment hemorrhoid of embodiment 12, preceding use is slept, one time a day, patient cleans affected part,
Emulsifiable concentrate is coated in the affected part of patient, two courses for the treatment of are used continuously in 15 days as a treatment course；
Control group 1：Using the tincture of the treatment hemorrhoid of comparative examples 1, preceding use is slept, one time a day, patient, which cleans, to suffer from
Place, tincture is embrocated in the affected part of patient, 15 days as a treatment course, two courses for the treatment of are used continuously；
Control group 2：Using the ointment of the treatment hemorrhoid of comparative examples 2, preceding use is slept, one time a day, patient, which cleans, to suffer from
Ointment, is coated in the affected part of patient by place, and two courses for the treatment of are used continuously in 15 days as a treatment course；
Control group 3：Using the emulsifiable concentrate of the treatment hemorrhoid of comparative examples 3, preceding use is slept, one time a day, patient, which cleans, to suffer from
Emulsifiable concentrate, is coated in the affected part of patient by place, and two courses for the treatment of are used continuously in 15 days as a treatment course；
Control group 4：Use commercially available acne cream (ingredient：Moschus, cow-bezoar, pearl, amber, borax, borneol, calamine, list
Sweet ester, paraben esters, deionized water), preceding use is slept, one time a day, patient cleans affected part, and acne cream is coated in the trouble of patient
Two courses for the treatment of are used continuously in place, 15 days as a treatment course.
3. classical symptom：Hematochezia, falling inflation sense, swelling, pain.
4. diagnostic criteria：
Recovery from illness：Clinical symptoms completely disappear.
It is effective：Clinical symptoms disappear substantially.
Effectively：Clinical symptom relief.
In vain：Substantially unchanged.
5. test result：
The curative effect comparison result for the treatment of group and control group is shown in Table 1；
The curative effect of 1 treatment group of table and control group compares
Treatment group and control group compare with otherness (P < 0.05).
6. effect determines：
By the comparison for the treatment of group and control group it is found that optical active starting materials composition of the invention and by optics of the invention
Preparation made from activated feedstock composition, efficient 100%, cure rate 93.9% can effectively treat hemorrhoid, efficient and healing
Rate is higher, and good effect, the period is short, and curative effect is significantly better than control group, and has no toxic side effect；There is apparent anti-inflammatory, analgesia
Hemostatic function；There is the apparent hemorrhoid effect that disappears for eliminating granulation swelling.
By treatment group 1 it is found that left-handed muskone and dencichine and 1 compared with the result of control group 1,4,2 propylene glycol
Synergistic effect, be conducive to improve tincture therapeutic effect, and can avoid excessive use ethyl alcohol irritative response, also avoid using
The tincture causes the shortcomings that red and swollen patient skin, burn feeling symptom；
By treatment group 2 it is found that left-handed muskone and dencichine and ethyl alcohol cooperate with work compared with the result of control group 2,4
With, be conducive to improve ointment therapeutic effect, left-handed muskone and ethyl alcohol combination reduce swelling；Inactivated bacteria effect obviously avoid using
The ointment causes the shortcomings that red and swollen patient skin, pruritis；
By treatment group 3 it is found that left-handed muskone and dencichine and ethyl alcohol -1.2 the third two compared with the result of control group 3,4
The synergistic effect of alcohol system, is conducive to the therapeutic effect for improving emulsifiable concentrate, and emulsifiable concentrate is thermodynamics meta-stable system, oil therein
The particle size range being mutually distributed in water is concentrated mainly between 0.01 micron to 0.1 micron, high with two-phase carrier systems matching degree；
It can avoid the stress reaction of osmotic resistance, also can avoid causing red and swollen patient skin, burn feeling and pruritus using the ointment
The shortcomings that shape.
Typical case 1：
Mr. Bai, female 28 years old, have foreign body sensation in anus, bleeding when stool, solution finishes is pressed with hand, and side enters for a good while, be diagnosed as in
Hemorrhoid.The drug of used a variety for the treatment of hemorrhoid, effect are undesirable.Treatment：It uses by the course for the treatment of by optical active starting materials of the invention
Preparation made from composition, cleans up patient affected part and surrounding skin, embrocates appropriate preparation patient's before sleeping every night
Affected part, one time a day, two courses for the treatment of are used continuously in 15 days as a treatment course.After treating 1 course for the treatment of, patient symptom mitigates.Continue
Using 1 course for the treatment of, symptom is completely disappeared.1 course for the treatment of is continued to use, is consolidated.Without recurrence after follow-up investigation discovery 1 year.
Typical case 2：
Liu, male, 39 years old, hepatic portal had foreign body sensation outside, cannot be sent into anus, be not easy bleeding, pain is diagnosed as external piles.With
The drug of a variety for the treatment of hemorrhoid is crossed, effect is undesirable.Treatment：It uses by the course for the treatment of by optical active starting materials composition of the invention
Preparation obtained, cleans up patient affected part and surrounding skin, appropriate preparation is coated in the affected part of patient, often before sleeping every night
Day 1 time, two courses for the treatment of are used continuously in 15 days as a treatment course.After treating 1 course for the treatment of, patient symptom mitigates.Continue to use 1
The course for the treatment of, symptom completely disappear.1 course for the treatment of is continued to use, is consolidated.Without recurrence after follow-up investigation discovery 1 year.
Typical case 3：
Huang, female 50 years old, there is foreign body sensation inside and outside anus, and bleeding when stool, pain is diagnosed as mixed hemorrhoid.It is used a variety of
The drug of hemorrhoid is treated, effect is undesirable.Treatment：It is used as made from optical active starting materials composition of the invention by the course for the treatment of
Preparation cleans up patient affected part and surrounding skin, and appropriate preparation is coated in the affected part of patient before sleeping every night, one time a day,
Two courses for the treatment of are used continuously in 15 days as a treatment course.After treating 1 course for the treatment of, patient symptom mitigates.Continue to use 1 course for the treatment of, disease
Shape completely disappears.1 course for the treatment of is continued to use, is consolidated.Without recurrence after follow-up investigation discovery 1 year.
Claims (12)
1. a kind of optical active starting materials composition, which is characterized in that the composition by following parts by weight bulk pharmaceutical chemicals preparation and
At：
Left-handed muskone 30-200 dencichine 10-100.
2. composition according to claim 1, which is characterized in that the composition is prepared by the bulk pharmaceutical chemicals of following parts by weight
It forms：
Left-handed 115 dencichine 55 of muskone.
3. the preparation as made from the described in any item compositions of claim 1-2 and auxiliary material, which is characterized in that the preparation includes
Any one in tincture, abrasive cleaner, ointment, emulsifiable concentrate, creme, suppository, film, transdermal patch, paste or liniment.
4. preparation according to claim 3, which is characterized in that the preparation is tincture, and the tincture includes following weight
The composition and auxiliary material of part composition：
5. preparation according to claim 3, which is characterized in that the preparation is ointment, and the ointment includes following
The composition and auxiliary material of parts by weight composition：
6. preparation according to claim 3, which is characterized in that preparation used is emulsifiable concentrate, and the emulsifiable concentrate includes following
The composition and auxiliary material of parts by weight composition：
7. a kind of preparation method of preparation as claimed in claim 5, which is characterized in that described method includes following steps：
(1) dencichine of recipe quantity is ground into fine powder 1, by the left-handed muskone and ethyl alcohol of recipe quantity with 1:2 parts by weight
Number ratio mixes to obtain solution 1, and the fine powder 1 and solution 1 are uniformly mixed, and composition is made；
(2) vitamin K for entering recipe quantity in the composition obtained to step (1) continuously adds the two of recipe quantity after completely dissolution
Methyl sulfoxide and 1,2-PD, sufficiently dissolution and after mixing, obtain A mixture；
(3) atoleine of recipe quantity, vaseline, glycerin monostearate, glycerol, octadecanol and purified water are placed in glass
It is heated to 75-80 DEG C in reaction kettle, when at the uniform velocity stirring 20-25min is down to 35-45 DEG C to kettle temperature, the A that step (2) obtain is added
Mixture continues to stir 15-20min, stops heating and stirring；Then raw material in kettle is placed in vacuum homogeneous emulsifying machine newborn
Change, is cooled to room temperature to get ointment.
8. a kind of preparation method of preparation as claimed in claim 6, which is characterized in that described method includes following steps：
(1) dencichine of recipe quantity is ground into fine powder 1, by the left-handed muskone and ethyl alcohol of recipe quantity with 1:2 parts by weight
Number ratio mixes to obtain solution 1, and the fine powder 1 and solution 1 are uniformly mixed, and composition is made；
(2) vitamin K of recipe quantity is added in the composition obtained to step (1), sufficiently dissolves, obtains mixed solution I, it is spare；
(3) lanolin of recipe quantity, glycerin monostearate, octadecanol and purified water are placed in glass reaction kettle and are heated to
75-80 DEG C, when at the uniform velocity stirring 5-10min is down to 35-45 DEG C to kettle temperature, the mixed solution I that step (2) obtain is added, continues to stir
5-15min is mixed, heating and stirring are stopped；Then raw material in kettle is placed in vacuum homogeneous emulsifying machine and is emulsified, is cooled to room temperature, i.e.,
Obtain emulsifiable concentrate.
9. a kind of application of described in any item compositions of claim 1-2 in the drug of preparation treatment hemorrhoid.
10. a kind of preparation method of tincture, which is characterized in that
The tincture includes the composition and auxiliary material of following parts by weight composition：
Described method includes following steps：
(1) dencichine of 10g is ground into fine powder 1, by the left-handed muskone and ethyl alcohol of 30g with 1:2 weight fraction ratio is mixed
It is even to obtain solution 1, the fine powder 1 and solution 1 are uniformly mixed, composition I is made；
(2) the composition I that step (1) obtains is placed in glass reaction kettle and is heated to 30 DEG C, at the uniform velocity stirring 15min, stirring
The 1,2-PD of the dimethyl sulfoxide of recipe quantity, the ethyl alcohol of recipe quantity, recipe quantity is sequentially added simultaneously, keeps 30 DEG C of temperature
Degree, and continue to stir 20min to being uniformly mixed, stop heating, it, will be empty from the compression that pressure is 0.08Mpa after being cooled to room temperature
Material bottom is introduced at the reacted kettle feed opening of Φ 10mm hose accessed on gas cylinder, brushes 60min, after being then allowed to stand 3h ageing
Light yellow transparent liquid is obtained to get tincture.
11. a kind of preparation method of tincture, which is characterized in that
The tincture includes the composition and auxiliary material of following parts by weight composition：
Described method includes following steps：
(1) dencichine of 100g is ground into fine powder 1, by the left-handed muskone and ethyl alcohol of 200g with 1:2 weight fraction ratio
Solution 1 is mixed to obtain, the fine powder 1 and solution 1 are uniformly mixed, composition II is made；
(2) the composition II that step (1) obtains is placed in glass reaction kettle and is heated to 35 DEG C, at the uniform velocity stirring 20min, stirring
The 1,2-PD of the dimethyl sulfoxide of recipe quantity, the ethyl alcohol of recipe quantity, recipe quantity is sequentially added simultaneously, keeps 35 DEG C of temperature
Degree, and continue to stir 30min to being uniformly mixed, stop heating, it, will be empty from the compression that pressure is 0.08Mpa after being cooled to room temperature
Material bottom is introduced at the reacted kettle feed opening of Φ 10mm hose accessed on gas cylinder, brushes 60min, after being then allowed to stand 5h ageing
Light yellow transparent liquid is obtained to get tincture.
12. a kind of preparation method of tincture, which is characterized in that
The tincture includes the composition and auxiliary material of following parts by weight composition：
Described method includes following steps：
(1) dencichine of 55g is ground into fine powder 1, by the left-handed muskone and ethyl alcohol of 115g with 1:2 weight fraction ratio is mixed
It is even to obtain solution 1, the fine powder 1 and solution 1 are uniformly mixed, composition III is made；
(2) the composition III that step (1) obtains is placed in glass reaction kettle and is heated to 33 DEG C, at the uniform velocity stirring 18min, stirring
While sequentially add the 1,2-PD of the dimethyl sulfoxide of recipe quantity, the ethyl alcohol of recipe quantity, recipe quantity, keep 33 DEG C of temperature
Degree, and continue to stir 25min to being uniformly mixed, stop heating, it, will be empty from the compression that pressure is 0.08Mpa after being cooled to room temperature
Material bottom is introduced at the reacted kettle feed opening of Φ 10mm hose accessed on gas cylinder, brushes 60min, after being then allowed to stand 4h ageing
Light yellow transparent liquid is obtained to get tincture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510058942.XA CN105982882B (en) | 2015-02-03 | 2015-02-03 | A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510058942.XA CN105982882B (en) | 2015-02-03 | 2015-02-03 | A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105982882A CN105982882A (en) | 2016-10-05 |
| CN105982882B true CN105982882B (en) | 2018-11-16 |
Family
ID=57037852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510058942.XA Active CN105982882B (en) | 2015-02-03 | 2015-02-03 | A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105982882B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853122A (en) * | 2017-05-15 | 2018-11-23 | 中微知著药物手性技术（大连）有限公司 | For treating the composition of pathogenic fungi of superficial mycosis |
| CN109662988A (en) * | 2019-01-22 | 2019-04-23 | 中微知著药物手性技术（大连）有限公司 | The feedstock composition and preparation method for treating leucoderma |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403142A (en) * | 2002-10-18 | 2003-03-19 | 武汉马应龙药业集团股份有限公司 | Suppository for treating piles and other anorectal diseases and its prepn |
| CN1623535A (en) * | 2004-08-11 | 2005-06-08 | 昆明圣火制药有限责任公司 | Medicinal composition for treating bleeding disease and its use |
| CN102885893A (en) * | 2012-10-16 | 2013-01-23 | 王昌伟 | Pharmaceutical composition for treating haemorrhoids |
-
2015
- 2015-02-03 CN CN201510058942.XA patent/CN105982882B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403142A (en) * | 2002-10-18 | 2003-03-19 | 武汉马应龙药业集团股份有限公司 | Suppository for treating piles and other anorectal diseases and its prepn |
| CN1623535A (en) * | 2004-08-11 | 2005-06-08 | 昆明圣火制药有限责任公司 | Medicinal composition for treating bleeding disease and its use |
| CN102885893A (en) * | 2012-10-16 | 2013-01-23 | 王昌伟 | Pharmaceutical composition for treating haemorrhoids |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105982882A (en) | 2016-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3466447B1 (en) | Pharmaceutical composition for treating multiple forms of skin wounds and manufacturing method thereof | |
| CA2105313A1 (en) | Therapeutic and cosmetic compositions for treatment of skin | |
| WO2000009121A1 (en) | Anti-inflammatory analgesics | |
| CN103169928A (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| KR20070054222A (en) | Medicine having analgesic effects | |
| EP0884042A1 (en) | Medicament and method of treating an organism with medicaments | |
| CN101292997A (en) | Pharmaceutical composition for treating empyrosis or gastric ulcer, and preparation method thereof | |
| CN105982882B (en) | A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid | |
| CN101669986A (en) | Compound gel preparation containing sophora alopecuroide oil | |
| CN110974861B (en) | Blumea balsamifera oil liposome | |
| CN107468798A (en) | A kind of composition for treating acne and its preparation method and application | |
| CN112521389B (en) | Medicament and method for promoting wound healing | |
| CN101036660A (en) | Estrogen gel medicine and preparation method thereof | |
| CN113491681A (en) | Application of cannabinoid molecule CBG in preparation of inflammatory pain medicines and medicinal preparation | |
| CN102266408B (en) | Use of gardenia extract and borneol effective ingredients in Chinese medicine preparation for intervening in cutaneous prutitus | |
| CN110302228A (en) | A kind of biological agent that treating hemorrhoid and its application | |
| CN113713000B (en) | Main medicine component composition for treating sore carbuncle, burn, scald and acne, sustained and controlled release pharmaceutical preparation, and preparation method and application thereof | |
| KR20150102327A (en) | Production of antlers and medicinal herbs extract for arthritis care medicine | |
| CN108272991A (en) | A kind of anaesthetic and its manufacturing process of removing heat from blood blood pressure lowering | |
| JP3652865B2 (en) | Mixture of lactic acid condensate and composition containing the same | |
| CN109846861B (en) | Externally applied Mongolian medicine plaster and preparation method thereof | |
| KR20080105857A (en) | A composite, its manufacturing process and medication for healing hemorrhoids | |
| RU2357747C1 (en) | Method of psoriatic disease treatment | |
| CN108853122A (en) | For treating the composition of pathogenic fungi of superficial mycosis | |
| CN106267134A (en) | A kind of anti-inflammatory analgesic Chinese medicine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| OL01 | Intention to license declared | ||
| OL01 | Intention to license declared |